Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant sintilimab combined with chemotherapy and radical surgery for locally advanced thymic epithelial tumors
ChiCTR2000036033Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in thymic malignancies (TET), sponsored by Shanghai Pulmonary Hospital. Primary endpoints: Main pathological remission and Drug safety. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
thymic malignancies (TET)
Beyond the preview
Go deeper on ChiCTR2000036033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036033.